Like other big global OTC players, Bayer Consumer Health is stepping up its investment in digital self-care. In the first part of an exclusive two-part interview, HBW Insight interviews the company's head of R&D and chief scientific officer David Evendon-Challis to dig deeper into the rationale for setting up a new 'precision health' business unit.

There are predictions that precision health will be up to 20% of the consumer health market.
Bayer Consumer Health’s head of R&D and chief scientific officer David Evendon-Challis

Related resources

Biopharma professional on laptop browsing Pink Sheet for global policy and regulatory insights.
MAY 01, 2022
Regulatory & Compliance

Your Keys to Understanding EU Transparency

A collection of Pink Sheet articles covering evolving EU regulations on clinical trial disclosure and transparency

JUL 04, 2023

Bayer Consumer Health Exec Cites the ‘Huge Potential’ of OTC Digital Therapeutics, AI

Bayer Consumer Health's R&D head/chief scientific officer cites the opportunities in a new generation of OTC digital therapeutics and AI-driven self-care.